Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avalo Therapeutics (AVTX) Receivables (2016 - 2023)

Avalo Therapeutics filings provide 8 years of Receivables readings, the most recent being $44000.0 for Q2 2023.

  • On a quarterly basis, Receivables fell 97.62% to $44000.0 in Q2 2023 year-over-year; TTM through Jun 2023 was $44000.0, a 97.62% decrease, with the full-year FY2022 number at $1.0 million, down 79.16% from a year prior.
  • Receivables hit $44000.0 in Q2 2023 for Avalo Therapeutics, down from $1.9 million in the prior quarter.
  • In the past five years, Receivables ranged from a high of $8.2 million in Q1 2019 to a low of $44000.0 in Q2 2023.
  • Median Receivables over the past 5 years was $4.3 million (2020), compared with a mean of $3.9 million.
  • Biggest five-year swings in Receivables: skyrocketed 32.68% in 2020 and later plummeted 97.62% in 2023.
  • Avalo Therapeutics' Receivables stood at $5.2 million in 2019, then decreased by 16.35% to $4.4 million in 2020, then grew by 9.44% to $4.8 million in 2021, then tumbled by 60.01% to $1.9 million in 2022, then tumbled by 97.71% to $44000.0 in 2023.
  • The last three reported values for Receivables were $44000.0 (Q2 2023), $1.9 million (Q4 2022), and $1.3 million (Q3 2022) per Business Quant data.